e-cigarette

This intervention refers to a specific electronic nicotine delivery system (e-cigarette) utilized in clinical research led by The University of Texas Health Science Center, Houston. The system comprises a SmokTech 3.3 V, 1000 mAh battery and a 1.5 Ohm dual-coil cartomizer, which is filled with a tobacco-flavored e-liquid containing 36 mg/ml of nicotine in a 70% propylene glycol and 30% vegetable glycerin base (manufactured by AVAIL). The primary therapeutic objective in the context of tobacco use disorder is smoking reduction or cessation, particularly in specialized populations such as individuals with schizophrenia. Nicotine delivered via inhalation acts as an agonist at nicotinic acetylcholine receptors (nAChRs), providing a pharmacological substitute for combustible tobacco to mitigate withdrawal symptoms and cravings. In the associated clinical trial, this e-cigarette is evaluated as an adjunct to standard nicotine replacement therapy (nicotine patches).

Other names

electronic nicotine delivery systemENDSelectronic cigarette